

Form PTC-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 018733/1060		SERIAL NO. 09/965,796 <i>Unassigned</i>	
INFORMATION DISCLOSURE CITATION Submitted October 1, 2001 <i>(Use several sheets if necessary)</i>				APPLICANT David M. GOLDENBERG		GROUP ART UNIT 1642 <i>Unassigned</i>	
				FILING DATE October 1, 2001			

1997 U.S. P.O.
 09/965796
 10/01/01

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
anh	A1	5,686,072	02/1994	Uhr et al.			
anh	A2	5,484,892	01/1996	Tedder et al.			
	A3	5,686,072	11/11/97	Uhr et al.	<i>DUPLICATE REFERENCE / SAME AS A1</i>		

FOREIGN PATENT DOCUMENTS								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
anh	A4	EP 510 949 A2	04/1992	Europe				
	A5	WO 95/09917	04/1995	WO				
	A6	WO 98/42378	01/1998	WO				
	A7	WO 99/02567	01/1999	WO				
	A8	WO 96/04925	02/1996	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
anh	A9	S. Kiesel et al. "Removal of Cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement..." Leukemia Research vol. II, no. 12, 1987, pages 1119-1125
	A10	O. Press, "Prospects for the management on non-Hodgkin's lymphomas with monoclonal antibodies and Immunoconjugates." Cancer Journal from Scientific American, vol. 4, no. suppl. 2, July 1998.
anh	A11	D. Maloney et al. "Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal Antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma" Blood, vol. 84, no. 8, 1994, pages 2457-2466.
	A12	M. Ghetie et al. "A Combination of immunotoxins and chemotherapy can cure SCID mice of Human B-Cell Tumors" The Faseb Journal, vol. 8, no. 4, 1994.
anh	A13	D. Flavell et al., "Systematic Therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-Saporin Immunotoxin, is curative of human B-Cell..." Cancer Research, vol. 57, no. 21, 1997 Nov, pages 4824-9.
	A14	Green et al., "Antigen-specific human monoclonal antibodies from mice engineered with hum.Ig heavy and light Chain YACS", Nature Genetic, vol. 7, pp. 13-21, volume 1, May 1994.
anh	A15	R. French et al., "Response of B-cell lymphomato a combination of bispecific antibodies and saporin" Leukemia Research, vol. 20, no. 7, July 1996, pages 607-617.

EXAMINER <i>anh</i>	DATE CONSIDERED <i>01/06/2004</i>
------------------------	--------------------------------------

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 018733/1060		SERIAL NO. <u>091 965,796</u> Unassigned	
INFORMATION DISCLOSURE CITATION Submitted October 1, 2001 (Use several sheets if necessary)				APPLICANT David M. GOLDENBERG			
				FILING DATE October 1, 2001		GROUP ART UNIT <u>1642</u> Unassigned	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>amh</i>	A16	C. Renner et al. "Monoclonal antibodies in the treatment of non-Hodgkin's Lymphoma: recent results and Future Prospects" Leukemia, Vol. 11, no. suppl.2, April 1997, <u>555-59</u> .					
	A17	J. Leonard et al. "Epratuzumab, a new anti-CD22, humanized, monoclonal antibody for the therapy of non-Hodgkin's lymphoma (NHL): phase I/II trial results" Blood, vol. 94, no. 10-suppl.-1-part.1, 1999.					
<i>amh</i>	A18	Kaminski et al., "Radioimmunotherapy of B-Cell lymphoma with [131] Anti-B1 [Anti-CD20] Antibody", New England J. of Medicine 329(7): 459-465, <u>August 12, 1993</u> .					
	A19	Vuist et al., "Potentiation by interleukin 2 of burkitt's lymphoma therapy with Anti-Pan B (Anti-CD19) monoclonal antibodies in a mouse xenotransplantation model", Cancer Research, Vol 53, pp-819-825					
<i>amh</i>	A20	Juweid et al., "Treatment of non-hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22", Cancer Research (Suppl.) Vol. 55, pp 5899s-5907s, <u>December 1, 1995</u> .					
<i>amh</i>	A21	Kreitman, R. et al. Pseudomonas Exotoxin-based Immunotoxins containing the Antibody LL2 or LL2-Fab' Induce Regression of Subcutaneous human B-Cell Lymphomas in Mice, Cancer Research 53: 819-825, February 15, 1993.					
EXAMINER <i>Amf/Arri</i>				DATE CONSIDERED <u>01/06/2004</u>			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							